Polypoid Atypical Spitz Tumor With a Fibrosclerotic Stroma, CLIP2-BRAF Fusion, and Homozygous Loss of 9p21.
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
27
8
2019
medline:
24
11
2020
entrez:
27
8
2019
Statut:
ppublish
Résumé
We report a case of a polypoid atypical Spitz tumor with a prominent fibrosclerotic stromal component, harboring a CLIP2-BRAF fusion, which has hitherto been not reported in melanocytic lesions. The neoplasm occurred in a 78-year-old male patient and appeared microscopically as a predominantly dermal, barely symmetrical, polypoid lesion composed mainly of epithelioid cells showing moderate degree of nuclear pleomorphism with ample amphophilic cytoplasm arranged in nests, fascicles, or single units. The mitotic rate was 2/mm, and the mitoses were confined to the upper portion of the lesion. The Breslow thickness was 2.3 mm. The stroma contained conspicuous plumped fibroblasts and thickened collagen bundles associated with dilated medium-sized vessels. Focally, sclerotic areas were found. A moderately dense, lymphocyte-predominant inflammatory infiltrate scattered through the whole lesion was seen. Despite strong nuclear and cytoplasmic positivity of p16, FISH revealed homozygous loss in locus 9p21. A CLIP2-BRAF fusion was found by next-generation sequencing. No other genetic alterations including a TERT-promoter mutation was found. The patient is disease-free without recurrence or evidence of metastatic disease after 5 years and 2 months of follow-up.
Identifiants
pubmed: 31449064
doi: 10.1097/DAD.0000000000001502
pii: 00000372-202003000-00008
doi:
Substances chimiques
Microtubule-Associated Proteins
0
cytoplasmic linker protein 115
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
204-207Références
Barnhill RL. Spitz nevus. In: Barnhill RL, Piepkorn M, Busam KL, eds. Pathology of Melanocytic Nevi and Malignant Melanoma. 3rd ed. New York, PA: Springer-Verlag; 2014:155–184.
WHO Classification of Skin Tumours. 4th ed. Lyon, France: World Health Organization; 2018.
Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
Amin SM, Haugh AM, Lee CY, et al. A Comparison of morphologic and molecular features of BRAF, ALK, and NTRK1 fusion Spitzoid neoplasms. Am J Surg Pathol. 2017;41:491–498.
Busam KJ, Kutzner H, Cerroni L, et al. Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. Am J Surg Pathol. 2014;38:925–933.
Yeh I, de la Fouchardiere A, Pissaloux D, et al. Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am J Surg Pathol. 2015;39:581–591.
Yeh I, Busam KJ, McCalmont TH, et al. Filigree-like rete ridges, lobulated nests, rosette-like structures, and exaggerated maturation characterize spitz tumors with NTRK1 fusion. Am J Surg Pathol. 2019;43:737–746.
VandenBoom T, Quan VL, Zhang B, et al. Genomic fusions in pigmented spindle cell nevus of reed. Am J Surg Pathol. 2018;42:1042–1051.
Botton T, Yeh I, Nelson T, et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res. 2013;26:845–851.
Perron E, Pissaloux D, Neub A, et al. Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors. Virchow Arch. 2018;472:469–476.
Gerami P, Li G, Pouryazdanparast P, et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol. 2012;36:808–817.
Thomas NE, Edmiston SN, Tsai YS, et al. Utility of TERT promoter mutation for cutaneous primary melanoma. Am J Dermatopathol. 2019;41:264–272.
Skalova A, Vanecek T, Martinek P, et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol. 2018;42:234–246.
Dessars B, De Raeve LE, El HH, et al. Chromosomal translocations as a mechanism of BRAF activation in two cases oflarge congenital melanocytic nevi. J Invest Dermatol. 2007;127:1468–1470.
Kim HS, Jung M, Kang HN, et al. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene. 2017;36:3334–3345.
Turner J, Couts K, Sheren J, et al. Kinase gene fusions in defined subsets of melanoma. Pigment Cell Melanoma Res. 2017;30:53–62.
Ross JS, Wang K, Chmielecki J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138:881–890.
Menzies AM, Yeh I, Botton T, et al. Clinical activity of the MEK inhibitor trametinib in metasta- tic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res. 2015;28:607–610.
Hutchinson KE, Lipson D, Stephens PJ, et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res. 2013;19:6696–6702.
Massi G, LeBoit PE. Spitz nevus variants, polypid spitz nevus. In: Massi G, LeBoit PE, eds. Histological Diagnosis of Nevi and Melanoma. New York, PA: Springer; 2014:188.
Ludgate MW, Fullen DR, Lee J, et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer. 2009;115:631–641.
Gerami P, Scolyer RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013;37:676–684.
Lee S, Barnhill RL, Dummer R, et al. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep. 2015;5:11200.
Yazdan P, Cooper C, Sholl LM, et al. Comparative analysis of atypical spitz tumors with heterozygous versus homozygous 9p21 deletions for clinical outcomes, histomorphology, BRAF mutation, and p16 expression. Am J Surg Pathol. 2014;38:638–645.
Harms PW, Hocker TL, Zhao L, et al. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions. Hum Pathol. 2016;58:152–160.
Gerami P, Cooper C, Bajaj S, et al. Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol. 2013;37:1387–1394.
Lee CY, Sholl LM, Zhang B, et al. Atypical Spitzoid neoplasms in childhood: a molecular and outcome study. Am J Dermatopathol. 2016;39:181–186.
Lazova R, Pornputtapong N, Halaban R, et al. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison to conventional melanocytic nevi and melanomas. Mod Pathol. 2017;30:640–649.
Busam KJ, Shah KN, Gerami P, et al. Reduced H3K27me3 expression is common in nodular melanomas of childhood associated with congenital melanocytic nevi but not in proliferative nodules. Am J Surg Pathol. 2017;41:396–404.
Wu G, Barnhill RL, Lee S, et al. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. Mod Pathol. 2016;29:359–369.
Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6:154–165.
Chakraborty R, Burke TM, Hampton OA, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016;128:2533–2537.
Jun HJ, Johnson H, Bronson RT, et al. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res. 2012;72:3764–3774.
Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27(suppl 3):iii4–iii15.